Antibody-Antigen Binding

B cells assemble unique heavy and light chain genes from V, D, and J gene segments. The combinatorial diversity (heavy chain V × D × J × light chain V × J) plus junctional diversity (random nucleotide additions and deletions at joining points) creates ~10¹⁰ specificities before any antigen exposure. After antigen contact, B cells in germinal centers undergo somatic hypermutation, rapidly mutating variable regions; selection favors those with improved binding. Class switching swaps the constant region (IgM to IgG, IgA, IgE) without changing specificity.

IgM is the first response, secreted as a pentamer with high avidity but low affinity. IgG dominates secondary responses, crosses the placenta, and has four subclasses with different effector functions. IgA is the mucosal antibody — secreted into gut, lung, and saliva as dimers — and is the most produced antibody by mass per day. IgE binds mast cells and drives allergic responses. IgD's role remains incompletely understood, present mainly on naive B cell surfaces.

By binding to functional sites on pathogens. Antibodies to viral receptor-binding domains block cell entry (the basis of COVID-19 monoclonals and respiratory syncytial virus prophylaxis). Antibodies to bacterial toxins prevent disease (tetanus and diphtheria immunity). Antibodies coating bacteria (opsonization) tag them for phagocytosis. The Fc region engages complement (classical pathway via C1q) and Fc receptors on macrophages, NK cells, and neutrophils, recruiting effector functions.

In germinal centers within lymph nodes, activated B cells proliferate rapidly while AID enzyme introduces point mutations in their variable region genes — somatic hypermutation. Daughter cells with mutated antibodies compete for limited antigen on follicular dendritic cells; only those with improved binding receive survival signals from T follicular helper cells. The result is exponential enrichment of high-affinity clones over weeks, raising affinity by 10² to 10⁴ fold during a single immune response.

Original hybridoma technique fused mouse B cells to myeloma cells for indefinite production, but mouse antibodies provoke immune responses in humans. Modern monoclonals are humanized (mouse CDRs grafted onto human framework) or fully human (transgenic mice with human Ig loci, or phage display libraries). Production is in CHO cells. Engineering modifications (Fc silencing, glycoengineering, bispecific formats, antibody-drug conjugates) tune effector functions for specific therapeutic goals.

ELISA captures antigen on a plate, then detects with an enzyme-linked secondary antibody producing a colorimetric signal. Lateral flow tests (used in rapid antigen tests) move sample across a strip with capture antibodies that produce a visible line. Western blots separate proteins by size first, then probe with specific antibody. Flow cytometry uses fluorescent antibodies against cell surface markers to phenotype individual cells at thousands per second. Each technique trades sensitivity, specificity, throughput, and quantitation differently.

Antibody deficiency syndromes (X-linked agammaglobulinemia, common variable immunodeficiency, IgA deficiency) cause recurrent encapsulated bacterial infections. Treatment is intravenous or subcutaneous immunoglobulin replacement. Conversely, antibodies that mistake self for foreign cause autoimmune disease — anti-dsDNA in lupus, anti-CCP in rheumatoid arthritis, anti-AChR in myasthenia gravis. The diversity that protects from infection also creates the substrate for self-recognition.